<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110955</url>
  </required_header>
  <id_info>
    <org_study_id>20030232</org_study_id>
    <nct_id>NCT00110955</nct_id>
  </id_info>
  <brief_title>Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effect of darbepoetin alfa against placebo for&#xD;
      the treatment of anemia in subjects with non-myeloid malignancies receiving multicycle&#xD;
      chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of red blood cell (RBC) transfusion from week 5 to End of Treatment Period (EOTP)</measure>
    <time_frame>from week 5 to EOTP</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of achieving a hemoglobin concentration of greater than or equal to 11 g/dL in the absence of RBC transfusions in the preceding 28 days from week 5 to EOTP</measure>
    <time_frame>from week 5 to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RBC transfusions from week 5 to EOTP</measure>
    <time_frame>from week 5 to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-Fatigue subscale score from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-G Physical Well-being subscale from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemoglobin concentration greater than 13.0 g/dL at any time on study</measure>
    <time_frame>at any time on study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FACT-G total score from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of an increase in hemoglobin concentration greater than or equal to 2 g/dL in a 28-day window and any negative clinical consequences</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EQ-5D Thermometer from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BSI Anxiety scale score from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BSI Depression scale score from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of caregiver hours from baseline to EOTP</measure>
    <time_frame>from baseline to EOTP</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of a confirmed antibody formation to darbepoetin alfa</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">391</enrollment>
  <condition>Anemia</condition>
  <condition>Non-Myeloid Malignancies</condition>
  <arm_group>
    <arm_group_label>Darbepoetin alfa - Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Q3W 300 mcg darbepoetin alfa</description>
    <arm_group_label>Darbepoetin alfa - Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Q3W dosing of placebo</description>
    <arm_group_label>Placebo- Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with non-myeloid malignancy&#xD;
&#xD;
          -  At least 12 additional weeks of cyclic cytotoxic chemotherapy anticipated regardless&#xD;
             of schedule&#xD;
&#xD;
          -  Hemoglobin concentration less than 11.0 g/dL within 24 hours before randomization&#xD;
&#xD;
          -  Adequate serum folate and vitamin B12&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          -  Of legal age at the time written informed consent is obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of seizure disorder&#xD;
&#xD;
          -  Known primary hematologic disorder causing anemia other than non-myeloid malignancies&#xD;
&#xD;
          -  Unstable/uncontrolled cardiac condition&#xD;
&#xD;
          -  Clinically significant inflammatory disease&#xD;
&#xD;
          -  Other diagnoses not related to the cancer which can cause anemia&#xD;
&#xD;
          -  Inadequate renal and liver function&#xD;
&#xD;
          -  Iron deficiency&#xD;
&#xD;
          -  Known positive test for HIV infection&#xD;
&#xD;
          -  Previously suspected of or confirmed to have neutralizing antibodies to rHuEPO&#xD;
&#xD;
          -  Received more than 2 red blood cell (RBC) transfusions within 4 weeks of&#xD;
             randomization; or any RBC transfusion within 14 days before randomization; or any&#xD;
             planned RBC transfusion between randomization and study day 1&#xD;
&#xD;
          -  Received any erythropoietic therapy within 4 weeks of study day 1 or any planned&#xD;
             erythropoietic therapy between randomization and study day 1&#xD;
&#xD;
          -  Other investigational procedures&#xD;
&#xD;
          -  Currently enrolled in or has not yet completed at least 30 days since ending other&#xD;
             investigational device or drug trial(s), or subject receiving other investigational&#xD;
             agent(s)&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Not using adequate contraceptive precautions&#xD;
&#xD;
          -  Previously randomized into this study&#xD;
&#xD;
          -  Known hypersensitivity to any products to be administered&#xD;
&#xD;
          -  Concerns for subject's compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf</url>
    <description>Notice regarding posted summaries of trial results</description>
  </link>
  <link>
    <url>http://download.veritasmedicine.com/REGFILES/amgen/20030232_Posting_Summ_NESP.pdf</url>
    <description>To access clinical trial results information click on this link</description>
  </link>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group. Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. Curr Med Res Opin. 2009 Sep;25(9):2109-20. doi: 10.1185/03007990903084164.</citation>
    <PMID>19601709</PMID>
  </results_reference>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>May 16, 2005</study_first_submitted>
  <study_first_submitted_qc>May 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2005</study_first_posted>
  <last_update_submitted>January 14, 2010</last_update_submitted>
  <last_update_submitted_qc>January 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Non-myeloid malignancy</keyword>
  <keyword>Chemotherapy-induced anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

